Sio Capital Management portfolio
Concentrated managerInvestment firmPortfolio as of Jun 30, 2026 (Q2 2026) · filed with the SEC on Aug 14, 2026 · data updated on Nov 5, 2026 · Q2 2026 13F (filing) ↗ · all its 13F filings ↗
A 13F shows the portfolio at quarter-end and is filed up to 45 days later: these are not real-time positions and they may have changed.
Sio Capital Management reported a $584M portfolio of 57 positions to the SEC as of the end of Q2 2026. Its largest positions are AVR, COR, MMS. During the quarter it opened Allogene Therapeutics and Globus Medical and exited Corcept Therapeutics and LivaNova.
Sections with a free account
What it reported after the quarter end (Q2 2026)
The 13F shows the portfolio as of Jun 30, 2026. Since then Sio Capital Management has filed these own trades with the SEC (Form 4, when it owns more than 10% of a company or holds a role in it) and stakes above 5% (13D and 13G). It is not everything it did: only what it must report before the next 13F.
Stake reported in the company · event of Sep 30, 2026 · filed Nov 3, 2026 · filing ↗
- 13GRainier Acquisition5.7 %
Stake reported in the company · event of Sep 30, 2026 · filed Nov 3, 2026 · filing ↗
Stake reported in the company · event of Sep 30, 2026 · filed Nov 3, 2026 · filing ↗
Stake reported in the company · event of Jun 30, 2026 · filed Jul 28, 2026 · filing ↗
Stake reported in the company · event of Jun 30, 2026 · filed Jul 28, 2026 · filing ↗
What changed this quarter
73 positions with a change (14 new, 9 added to, 21 trimmed, 29 sold); also, 1 exited through an acquisition or merger. 12 are listed here: those of 0.5 points of the portfolio or more (up to 12).
- Icon−71%fewer sharesReduced4.9% → 2.6%
- Dianthus Therapeutics−84%fewer sharesReduced4.5% → 1.0%
- Allogene Therapeutics+4.0 ppof portfolioNew— → 4.7%
- Corcept Therapeutics−3.9 ppof portfolioSold out3.9% → —
- LivaNova−3.9 ppof portfolioSold out3.9% → —
- Globus Medical+3.4 ppof portfolioNew— → 4.1%
- Cencora+72%more sharesIncreased4.6% → 8.4%
- IDEAYA Biosciences+2.6 ppof portfolioNew— → 3.1%
- Embecta−2.4 ppof portfolioSold out2.4% → —
- Cigna Group+2.3 ppof portfolioNew— → 2.7%
- Viatris+2.2 ppof portfolioNew— → 2.6%
- Abivax−2.2 ppof portfolioSold out2.2% → —
The figure on the right: for positions added to or trimmed, the change in the number of shares (%); for new and sold ones, the points of the portfolio moved (pp). Below, the portfolio weight before → after. Traded weight: what it bought or sold, excluding price effects.
Top holdings
- Anteris Technologies GlobalAVR9.4%
- CencoraCOR8.4%
- MaximusMMS6.6%
- Allogene TherapeuticsALLO4.7%
- Globus MedicalGMED4.1%
- GSKGSK3.9%
- Tyra BiosciencesTYRA3.8%
- Waystar HoldingWAY3.3%
- IDEAYA BiosciencesIDYA3.1%
- Oruka TherapeuticsORKA2.9%
- Cigna GroupCI2.7%
- SanofiSNY2.7%
- IconICLR2.6%
- ViatrisVTRS2.6%
- Cross Country Healthcare2.5%
“Since”: first quarter of the current run, unbroken until today. In the details, prices are the quarter-end prices of the quarters in which it added shares, per the 13F. The manager may have bought at any price within each quarter; the SEC only publishes the value at quarter end.
Portfolio by sector
- ● Health Care 89%
- ● Industrials 9%
- ● Information Technology 2%
How its portfolio changed (8 quarters)
Q2 2026: 57
Q2 2026: 50%
Q2 2026: 40.2%
Traded turnover: the weight it bought plus the weight it sold in the quarter, divided by two, excluding price moves. The plain “turnover” in the header does include that effect. With a free account: the full history and sectors over time.
Declared options (2)
Besides stocks, Sio Capital Management declared 1 put (they gain if the stock falls) and 1 call (they gain if it rises) with a notional of $20.8M. The 13F reports the value of the underlying shares, not the premium paid, so these figures look large and are not added to the portfolio. Nor does it say whether the option is bought or written, or its strike or expiry: it may be a hedge.
- PUTSELLAS Life Sciences GroupSLSnew this quarter$18.2M
- CALLHims & Hers HealthHIMSnew this quarter$2.6M
Stakes above 5% (13D/13G)
Companies where this filer reported holding 5% or more of the shares. It is the figure from its latest filing on each one; history since December 2024.
How we classify it
Investment firm, per its Form ADV of Mar 18, 2026 (high confidence).
The data, as reported: SIO CAPITAL MANAGEMENT, LLC (CRD 165989): 7.B private funds: 2 hedge (gross assets $685M); 5.D assets by client type: pooled vehicles 53%, other advisers 47% (of $1.3 bn)
The type comes from a rule applied to that data. If it looks wrong, tell us.
Similar managers by type and size
Same type of filer and a 13F portfolio value between a third and three times this one. It is not a comparison of what they hold.
- Land & Buildings Investment ManagementInvestment firm · $583M
- Global Frontier InvestmentsInvestment firm · $581M
- Prosight ManagementInvestment firm · $580M
- Nuance InvestmentsInvestment firm · $588M
- Solel PartnersInvestment firm · $588M
- Paradice Investment ManagementInvestment firm · $594M